Epigral Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Published 25 Aug 2026 | Chemicals & Petrochemicals | Market Cap: ₹4.9K Cr
Epigral targets a CAGR growth of 15% to 20% in both top line (sales/revenue) and bottom line over the next 3 to 5 years. Epigral targets a compound annual growth rate (CAGR) of 15% to 20% for both top-line and bottom-line over the next 3 to 5 years, driven by ramp-up of new capacities and growing market demand.
From Epigral's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Price
₹1,235
Market Cap
₹4.9K Cr
P/E Ratio
17.9
Revenue Rank
Margin Rank
How does Epigral rank in Chemicals & Petrochemicals?
Compare Epigral against every Chemicals & Petrochemicals company this quarter on revenue, margins and earnings-call signals.
Epigral — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹736 Cr, net profit ₹82 Cr.
Full financials →📊 Revenue & Sales Performance
Rank 2- →Epigral targets a CAGR growth of 15% to 20% in both top line (sales/revenue) and bottom line over the next 3 to 5 years.
- →Growth driven by ramping up existing capacities (chlorotoluenes, caustic soda, CPVC) and commissioning new capacities such as Epoxy Resin, Epichlorohydrin (ECH), and multipurpose plants.
- →The company aims to expand from approximately INR2,500 crores current revenue to around INR3,000-3,500 crores in the near term, and with all plants at optimal utilization, the top line could reach INR4,000+ crores over time.
- →Domestic demand, especially in infrastructure, renewable energy, automotive, and pharmaceutical/agrochemical intermediates, is expected to sustain double-digit volume growth.
- →Long-term focus includes capturing growing Indian market demand and eventual exports, especially to Europe post-FTA agreements.
- →Expectation of margin stability around 22%-25% with a 3-4 year gestation to reach peak utilization for new projects.
📈 Profitability & Margins
Rank 3- →Epigral targets a compound annual growth rate (CAGR) of 15% to 20% for both top-line and bottom-line over the next 3 to 5 years, driven by ramp-up of new capacities and growing market demand.
- →The company aims to maintain an EBITDA margin around 22%-25%, with epoxy resin projects expected to have lower margins but high asset turnover, keeping ROCE around 20%.
- →Profit after tax (PAT) grew 25% in Q1 FY27 compared to Q1 FY26, reflecting resilience despite a challenging environment.
- →Expansion into value-added products and integration of raw material production are expected to sustain earnings growth and improve operational efficiency.
- →Capacity additions in epoxy resin, multipurpose plants, and enhanced ECH capacity will contribute significantly to future revenue and profits.
- →While short-term margin fluctuations are possible due to market volatility, long-term earnings growth is expected to be consistent due to diversification and integration strategies.
🏗️ Capital Expenditure Plans
Yes- →Epigral Limited has approved a strategic capex plan for two new projects:
- → - Epoxy Resin & Formulations plant with 125,000 tons per annum capacity.
- → - A Multipurpose Plant (MPP) to manufacture downstream products of epichlorohydrin and chlorotoluenes value chain.
- →Total capex in chlorotoluenes around INR 250 crores has been done.
- →Combined peak revenue expected post these projects is INR 1,300 to 1,500 crores.
- →Overall capex including the MPP is expected to result in consolidated top line in the range of INR 700 to 800 crores initially.
- →Capex split: 40% internal accruals, 60% debt.
- →Estimated EBITDA margin for chlorotoluenes/MPP around 22%-23%.
- →Gestation/ramp-up period expected to be 1.5 to 2 years for optimum utilization.
- →A pilot plant for epoxy resin and MPP is to be operational by Q2 FY27 for product and customer approvals.
💰 Fundraising & Capital Structure
Yes- →For the ongoing capex of around INR600 crores, the company plans to fund approximately 60% through debt and 40% from internal accruals. (Page 15)
- →No specific mention of any new equity fundraising was made during the call.
- →Net debt stood at INR474 crores as of June 30, 2026, up from INR439 crores the previous year, mainly due to capex and lower earnings. (Page 5)
- →The company maintains a moderate net debt-to-EBITDA ratio of 0.8x as of June 30, 2026. (Page 5)
- →No announcement of fresh equity or debt fundraising was disclosed beyond the stated capex funding mix and utilizing internal cash flows.
- →The focus appears to be on completing current expansions with a blend of debt and internal funds, maintaining financial discipline. (Overall context)
📋 Order Book & Pipeline
No informationKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were Epigral Q1 FY27 results?
Epigral targets a CAGR growth of 15% to 20% in both top line (sales/revenue) and bottom line over the next 3 to 5 years. Epigral targets a compound annual growth rate (CAGR) of 15% to 20% for both top-line and bottom-line over the next 3 to 5 years, driven by ramp-up of new capacities and growing market demand.
What is Epigral share price analysis?
Epigral currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 17.9 with a market cap of ₹4,858 Cr. Investors should review the full earnings analysis for detailed insights.
Is Epigral planning capital expenditure?
Epigral Limited has approved a strategic capex plan for two new projects: - Epoxy Resin & Formulations plant with 125,000 tons per annum capacity.
Keep Epigral on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.